The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)

Publications

Li L, Wang Z, Cui L, Xu Y, Guan K, Zhao B

Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.

Clinical and translational allergy 2021 Jun;11;e12038 — 2021 Jun — e12038

Jingo K, Harada N, Nishioki T, Torasawa M, Yamada T, Asao T, Takagi H, Takeshige T, Ito J, Takahashi K

Anaphylaxis to three humanized antibodies for severe asthma: a case study.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2020;16;46 — 2020 — 46

Cox L, Lieberman P, Wallace D, Simons FE, Finegold I, Platts-Mills T, Schwartz L

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report.

The Journal of allergy and clinical immunology 2011 Jul;128;210-2 — 2011 Jul — 210-2

Kim HL, Leigh R, Becker A

Omalizumab: Practical considerations regarding the risk of anaphylaxis.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2010 Dec 03;6;32 — 2010 Dec 03 — 32

Lin RY, Rodriguez-Baez G, Bhargave GA

Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2009 Nov;103;442-5 — 2009 Nov — 442-5

Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P

The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update.

Respiratory medicine 2009 Aug;103;1098-113 — 2009 Aug — 1098-113

Limb SL, Starke PR, Lee CE, Chowdhury BA

Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.

The Journal of allergy and clinical immunology 2007 Dec;120;1378-81 — 2007 Dec — 1378-81

Chipps B

Systemic reaction to omalizumab.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2006 Aug;97;267 — 2006 Aug — 267

Dreyfus DH, Randolph CC

Characterization of an anaphylactoid reaction to omalizumab.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2006 Apr;96;624-7 — 2006 Apr — 624-7